Evidence map›Paper›PMID 31652721›Full record

ArticleCancers2019

Are

Lucie Jiraskova, Ales Ryska, Erik Jurjen Duintjer Tebbens, Helena Hornychova, Filip Cecka, Frantisek Staud, Lukas Cerveny

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lucie JiraskovaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. jiraskl2@faf.cuni.cz.
Ales RyskaThe Fingerland Department of Pathology, Faculty of Medicine and University Hospital Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. ales.ryska@fnhk.cz.ORCID 0000-0002-3051-2280
Erik Jurjen Duintjer TebbensDepartment of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. jurjend@faf.cuni.cz.ORCID 0000-0003-0553-854X
Helena HornychovaThe Fingerland Department of Pathology, Faculty of Medicine and University Hospital Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. helena.hornychova@fnhk.cz.
Filip CeckaDepartment of Surgery, Faculty of Medicine and University Hospital Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. filip.cecka@fnhk.cz.
Frantisek StaudDepartment of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. frantisek.staud@faf.cuni.cz.
Lukas CervenyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. cervenyl@faf.cuni.cz.ORCID 0000-0002-1313-306X
Charles University · CZ

Funding

European Regional Development Fund BBMRICZ EF16 013/0001674European Regional Development Fund EFSA-CDN (No. CZ.02.1.01/0.0/0.0/16_019/0000841) co-funded by ERDFGrantová Agentura, Univerzita Karlova 812216/C/2016Ministerstvo Školství, Mládeže a Tělovýchovy BBMRI-CZ LM2015089Univerzita Karlova v Praze PROGRES Q40/11Univerzita Karlova v Praze SVV 2017/260-414
6 · The paper itself

Abstract

Evidence on equilibrative nucleoside transporter 1 (ENT1) and microRNA-21 (miR‑21) is not yet sufficiently convincing to consider them as prognostic biomarkers for patients with pancreatic ductal adenocarcinoma (PDAC). Here, we investigated the prognostic value of

Indexed as

adjuvant gemcitabine monotherapyequilibrative nucleoside transporter 1miR-21neurogenic locus homolog protein 3prognostic biomarkerresected pancreatic ductal adenocarcinoma

Identifiers

PMID31652721
PMCPMC6893654
OpenAlexW2981467679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.